ResearcherUniversity Hospital UlmActive in the last 2 years
Chantal Allgöwer
Matched on OpenAlex author ID A5038750351. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 41
2024: 1 paper · 2025: none · 2026: 3 papers
Papers 4
- DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer. Co-author DOI 10.1002/advs.202417606↗
- Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.09.027↗
- An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. Co-author DOI 10.1186/s12943-025-02541-1↗
- An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
Closest collaborators
The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alexander Kleger · 4 shared papers, 2024–2026 · strength 0.78
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. DOI 10.1053/j.gastro.2026.09.027↗
- Paper An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. DOI 10.1186/s12943-025-02541-1↗
- Thomas Theodor Werner Seufferlein · 3 shared papers, 2026 · strength 0.62
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. DOI 10.1053/j.gastro.2026.09.027↗
- Paper An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. DOI 10.1186/s12943-025-02541-1↗
- Élodie Roger · 2 shared papers, 2026 · strength 0.42
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. DOI 10.1186/s12943-025-02541-1↗
- Michael Karl Melzer · 2 shared papers, 2026 · strength 0.42
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. DOI 10.1186/s12943-025-02541-1↗
- Dharini Srinivasan · 2 shared papers, 2026 · strength 0.42
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. DOI 10.1186/s12943-025-02541-1↗
- Peter Möller · 1 shared paper, 2026 · strength 0.22
- Frank Arnold · 1 shared paper, 2026 · strength 0.22
- Johann Gout · 1 shared paper, 2026 · strength 0.22
- Matthias J. Löhr · 1 shared paper, 2026 · strength 0.22
- Lukas Perkhofer · 1 shared paper, 2026 · strength 0.22
- Christopher J. Halbrook · 1 shared paper, 2026 · strength 0.20
- Alexander Muir · 1 shared paper, 2026 · strength 0.20
- Jennifer Brooke Valerin · 1 shared paper, 2026 · strength 0.20
- Austin D. Silva · 1 shared paper, 2026 · strength 0.20
- Tim Eiseler · 1 shared paper, 2026 · strength 0.20
- Rima Singh · 1 shared paper, 2026 · strength 0.20
- Kevin Christian Montecillo Gulay · 1 shared paper, 2026 · strength 0.20
- Alica K. Michels · 1 shared paper, 2026 · strength 0.20
- Aimee L Edinger · 1 shared paper, 2026 · strength 0.20
- David Kuang-Fu Chang · 1 shared paper, 2026 · strength 0.20
- Hervé Tiriac · 1 shared paper, 2026 · strength 0.20
- Paolo Riccardo Camisa · 1 shared paper, 2026 · strength 0.19
- Benedetta Ferrara · 1 shared paper, 2026 · strength 0.19
- Claus Jørgensen · 1 shared paper, 2026 · strength 0.19
- Anton Lahusen · 1 shared paper, 2026 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.